Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105 on ClinicalTrials.gov · last registry update 2026-01-13
An unusually large phase 2: 406 participants, more than double the 114 typical for the stage. The sponsor logged completion for 19 December 2025. Primary outcome, as filed: Change in HbA1c. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 406
- Started
- 2024-10-08
- Primary completion
- 2025-12-19 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.